China sxt pharmaceuticals, inc. (SXTC) 2024Q4 financial report shows revenue of 494.46K USD, with a YoY growth rate of -35.23%. This clearly indicates that China sxt pharmaceuticals, inc. (SXTC) is facing severe revenue challenges and a significant deterioration. To better understand the business situation, investors are advised to look beyond the revenue YoY, and closely examine trends in net profit, operating profit, and gross margin. In addition, leveraging third-party data such as Growin AI Value Analysis will provide a more comprehensive assessment of the operational pressure and potential financial risks faced by China sxt pharmaceuticals, inc. (SXTC).